NDAINJECTIONINJECTABLE
Approved
Aug 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DURANEST (epinephrine bitartrate; etidocaine hydrochloride) by AstraZeneca is 12. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1976.
Drug data last refreshed 6h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURANEST is a combination local anesthetic containing etidocaine hydrochloride and epinephrine bitartrate, designed for regional anesthesia and analgesia during surgical, dental, and diagnostic procedures. It works by blocking nerve impulse generation and conduction, with epinephrine acting as a vasoconstrictor to prolong anesthetic duration. The drug provides onset within 2-10 minutes with anesthetic effects lasting up to 7 hours.
LOE Approaching
As LOE approaches, expect reduced marketing investment and team consolidation; career growth limited to maintenance and generic transition planning roles.
Mechanism of Action
12.1 Mechanism of Action Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the…
Worked on DURANEST at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.